EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach

Anusuya Kawsar, Khawar Hussain iD, Andrew James Muinonen-Martin, Louise Fearfield

British Journal of Dermatology · 30.10.2023 · 189 (Supplement_1) · i3-i10

DOI: 10.1093/bjd/ljad257 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Dermatology, online erschienen am 30.10.2023. Verfasst von Anusuya Kawsar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Neoplasms, Skin Diseases, Exanthema. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: L'Oréal Dermatological Beauty, L’Oréal Dermatological Beauty.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies in the field of oncology. Their favourable outcomes in terms of efficacy and side-effect profile can be thwarted by the development of immune-related adverse events (irAEs). Cutaneous irAEs are relatively common in patients undergoing immunotherapy and include common inflammatory dermatoses (e.g. eczematous, psoriasiform and lichenoid phenotypes), maculopapular eruptions, pruritus and immunobullous disorders. Most of these reactions can be managed without ICIs having to be stopped completely; however, there are some life-threatening toxicities that dermatologists and oncologists should be aware of. In this review, we focus on how to recognize the commonly associated cutaneous irAEs, touching upon rarer reactions and red flags; finally, we provide guidance on their management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSkin DiseasesExanthemaHumansImmune Checkpoint InhibitorsSkinImmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • The Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Khawar Hussain

Förderung

  • L'Oréal Dermatological Beauty
  • L’Oréal Dermatological Beauty

Zitieren

APA

Kawsar, A., Hussain, K., Muinonen-Martin, A. J., & Fearfield, L. (2023). How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach. British Journal of Dermatology, 189(Supplement_1), i3-i10. https://doi.org/10.1093/bjd/ljad257

Vancouver

Kawsar A, Hussain K, Muinonen-Martin AJ, Fearfield L. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach. British Journal of Dermatology. 2023;189(Supplement_1):i3-i10. doi:10.1093/bjd/ljad257

BibTeX
@article{Kawsar2023,
  author = {Kawsar, Anusuya and Hussain, Khawar and Muinonen-Martin, Andrew James and Fearfield, Louise},
  title = {How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {189},
  number = {Supplement_1},
  pages = {i3--i10},
  doi = {10.1093/bjd/ljad257}
}
Kostenlos starten →